{"corpus_id":205617746,"paper_sha":"d743d68ed9cb36e3569218c460f35c883923746d","doi":"10.1038/s41598-017-14385-x","arxiv_id":null,"pmid":29093504,"pmcid":"5666021","mag_id":2766179504,"dblp_id":null,"acl_id":null,"title":"Mycobacterial genomic DNA from used Xpert MTB/RIF cartridges can be utilised for accurate second-line genotypic drug susceptibility testing and spoligotyping","year":2017,"publication_date":"2017-11-01","venue":"Scientific Reports","journal":{"name":"Scientific Reports","pages":null,"volume":"7"},"journal_issn":null,"journal_title":null,"publication_types":["JournalArticle"],"pubmed_pub_types":["Journal Article","Research Support, Non-U.S. Gov't"],"s2_fields_of_study":["Medicine"],"reference_count":39,"citation_count":16,"influential_citation_count":0,"is_open_access":true,"arxiv_categories":null,"arxiv_license":null,"arxiv_journal_ref":null,"mesh_headings":[{"d":"DNA, Bacterial","mj":false,"qs":[{"q":"analysis","mj":true,"ui":"Q000032"}],"ui":"D004269"},{"d":"Drug Resistance, Bacterial","mj":false,"qs":[{"q":"genetics","mj":true,"ui":"Q000235"}],"ui":"D024881"},{"d":"Genome, Bacterial","mj":false,"ui":"D016680"},{"d":"Humans","mj":false,"ui":"D006801"},{"d":"Mycobacterium tuberculosis","mj":false,"qs":[{"q":"genetics","mj":true,"ui":"Q000235"},{"q":"isolation & purification","mj":false,"ui":"Q000302"}],"ui":"D009169"},{"d":"Rifampin","mj":false,"qs":[{"q":"pharmacology","mj":false,"ui":"Q000494"}],"ui":"D012293"},{"d":"Specimen Handling","mj":false,"qs":[{"q":"methods","mj":true,"ui":"Q000379"},{"q":"standards","mj":false,"ui":"Q000592"}],"ui":"D013048"},{"d":"Sputum","mj":false,"qs":[{"q":"microbiology","mj":false,"ui":"Q000382"}],"ui":"D013183"},{"d":"Tuberculosis","mj":false,"qs":[{"q":"diagnosis","mj":true,"ui":"Q000175"}],"ui":"D014376"}],"chemicals":[{"n":"DNA, Bacterial","ui":"D004269","reg":"0"},{"n":"Rifampin","ui":"D012293","reg":"VJT6J7R4TR"}],"comments_corrections":null,"source_flags":5,"s2_open_access_pdf_url":"https://www.nature.com/articles/s41598-017-14385-x.pdf","s2_open_access_landing_url":"https://www.semanticscholar.org/paper/d743d68ed9cb36e3569218c460f35c883923746d","s2_open_access_license":"CCBY","s2_open_access_status":"GOLD","pmc_open_access_pdf_url":null,"pmc_open_access_landing_url":null,"pmc_open_access_license":null,"pmc_open_access_status":null,"unpaywall_open_access_pdf_url":null,"unpaywall_open_access_landing_url":null,"unpaywall_open_access_license":null,"unpaywall_open_access_status":null,"abstract":"Xpert MTB/RIF (Xpert) is a widely-used test for tuberculosis (TB) and rifampicin-resistance. Second-line drug susceptibility testing (DST), which is recommended by policymakers, typically requires additional specimen collection that delays effective treatment initiation. We examined whether cartridge extract (CE) from used Xpert TB-positive cartridges was, without downstream DNA extraction or purification, suitable for both genotypic DST (MTBDRplus, MTBDRsl), which may permit patients to rapidly receive a XDR-TB diagnosis from a single specimen, and spoligotyping, which could facilitate routine genotyping. To determine the limit-of-detection and diagnostic accuracy, CEs from dilution series of drug-susceptible and -resistant bacilli were tested (MTBDRplus, MTBDRsl). Xpert TB-positive patient sputa CEs (n = 85) were tested (56 Xpert-rifampicin-susceptible, MTBDRplus and MTBDRsl; 29 Xpert-rifampicin-resistant, MTBDRsl). Spoligotyping was done on CEs from dilution series and patient sputa (n = 10). MTBDRplus had high non-valid result rates. MTBDRsl on CEs from dilutions ≥103CFU/ml (CT ≤ 24, >“low” Xpert semiquantitation category) was accurate, had low indeterminate rates and, on CE from sputa, highly concordant with MTBDRsl isolate results. CE spoligotyping results from dilutions ≥103CFU/ml and sputa were correct. MTBDRsl and spoligotyping on CE are thus highly feasible. These findings reduce the need for additional specimen collection and culture, for which capacity is limited in high-burden countries, and have implications for diagnostic laboratories and TB molecular epidemiology.","claims":[{"public_id":"cl_3d539cf2caf7e7bc3eb9b3fc6ae77a45","status":"active","text":"Cartridge extract from used Xpert MTB/RIF TB-positive cartridges can be used directly, without downstream DNA extraction or purification, for second-line genotypic drug susceptibility testing and spoligotyping.","confidence":0.97,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_3d539cf2caf7e7bc3eb9b3fc6ae77a45"},{"public_id":"cl_6d0d841d7bc45892eeb8ca39859be282","status":"active","text":"MTBDRplus had high non-valid result rates on cartridge extracts.","confidence":0.9,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_6d0d841d7bc45892eeb8ca39859be282"},{"public_id":"cl_e65d4e666a6c95f7ef28698bd93f2e90","status":"active","text":"MTBDRsl on cartridge extracts from dilutions at or above 10^3 CFU/ml was accurate and had low indeterminate rates.","confidence":0.95,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_e65d4e666a6c95f7ef28698bd93f2e90"},{"public_id":"cl_63ec4ab66b51a91708ecf17b842490f5","status":"active","text":"MTBDRsl results from patient sputum cartridge extracts were highly concordant with MTBDRsl isolate results.","confidence":0.93,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_63ec4ab66b51a91708ecf17b842490f5"},{"public_id":"cl_6637a3d9772f7d84828f06dc3ba094e3","status":"active","text":"Spoligotyping on cartridge extracts from dilutions at or above 10^3 CFU/ml and from patient sputum produced correct results.","confidence":0.95,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_6637a3d9772f7d84828f06dc3ba094e3"}],"concepts":[{"public_id":"co_078dab0a56099b93339218916e358ad7","status":"active","name":"drug-susceptible bacilli","description":"Mycobacterial bacilli not resistant to the tested anti-tuberculosis drugs.","types":["microbial material"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_078dab0a56099b93339218916e358ad7"},{"public_id":"co_19768412866ff019ee9f6073c378dea7","status":"active","name":"10^3 CFU/ml","description":"A bacillary concentration threshold used here as the detection and performance cutoff.","types":["measurement threshold"],"aliases":["103 CFU/ml"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_19768412866ff019ee9f6073c378dea7"},{"public_id":"co_1df6b5f74a9296c01feb4540f2e583ac","status":"active","name":"second-line genotypic drug susceptibility testing","description":"Genotypic testing used to assess resistance to second-line anti-tuberculosis drugs.","types":["diagnostic test"],"aliases":["second-line DST"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_1df6b5f74a9296c01feb4540f2e583ac"},{"public_id":"co_305b368e249f99e1cb218981712f9e3b","status":"active","name":"drug-resistant bacilli","description":"Mycobacterial bacilli resistant to one or more tested anti-tuberculosis drugs.","types":["microbial material"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_305b368e249f99e1cb218981712f9e3b"},{"public_id":"co_3e87d610520beca3018f7a7f256cc8da","status":"active","name":"Xpert MTB/RIF","description":"A widely used molecular assay for tuberculosis detection and rifampicin resistance testing.","types":["diagnostic test"],"aliases":["Xpert"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_3e87d610520beca3018f7a7f256cc8da"},{"public_id":"co_61a1cd96eb602cb3579f9e900fa9823f","status":"active","name":"patient sputum","description":"Sputum samples collected from tuberculosis patients and used for cartridge extract testing.","types":["specimen"],"aliases":["sputa"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_61a1cd96eb602cb3579f9e900fa9823f"},{"public_id":"co_742d16c4c2a7f1cc57240a0d7e61f560","status":"active","name":"cartridge extract","description":"Material recovered from used Xpert MTB/RIF cartridges for downstream molecular testing.","types":["sample material"],"aliases":["CE"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_742d16c4c2a7f1cc57240a0d7e61f560"},{"public_id":"co_998fab217d6db8a6d864e0694c6b0792","status":"active","name":"MTBDRplus","description":"A molecular line probe assay used for genotypic drug resistance testing.","types":["assay"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_998fab217d6db8a6d864e0694c6b0792"},{"public_id":"co_9d5147f5dd1d00a4091d9bc49e96e9de","status":"active","name":"MTBDRsl","description":"A molecular line probe assay used for second-line tuberculosis drug resistance testing.","types":["assay"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_9d5147f5dd1d00a4091d9bc49e96e9de"},{"public_id":"co_e106fbaa9da57a18af58fd6562f3cf65","status":"active","name":"spoligotyping","description":"A genotyping method that profiles mycobacterial strains using spacer patterns in the direct repeat region.","types":["genotyping method"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_e106fbaa9da57a18af58fd6562f3cf65"}],"external_ids":{"DOI":"10.1038/s41598-017-14385-x","ArXiv":null,"PubMed":29093504,"PubMedCentral":"5666021","MAG":2766179504,"DBLP":null,"ACL":null},"open_access":{"is_open_access":true,"pdf_url":"https://www.nature.com/articles/s41598-017-14385-x.pdf","landing_url":"https://www.semanticscholar.org/paper/d743d68ed9cb36e3569218c460f35c883923746d","source":"semantic_scholar","pdf_url_source":"semantic_scholar_open_access_pdf","license":"CCBY","status":"GOLD","reason":null},"reference_availability":{"status":"available","references_indexed":true,"full_text_available":false,"full_text_source":null,"count_basis":"semantic_scholar_metadata","extraction_status":"not_applicable","reason":null},"source":{"provider":"episteme2","base_corpus":"semantic_scholar_dump","freshness_mode":"unknown","basis":["semantic_scholar_metadata","postgres_metadata"],"limits":["paper metadata is based on indexed upstream scholarly datasets","claims and concepts are available only for extracted papers","absence of claims or concepts means no extracted graph data is available in this response"],"status":"available","degraded":false,"degraded_reasons":[],"diagnostics":{"status":"available","degraded":false,"degraded_reasons":[],"metadata_status":"available","graph_status":"available","abstract_status":"available"},"source_flags":5},"paper_id":631530,"paper_uid":"a27e8af3-cb30-48d7-a49e-1258867acbdb","canonical_identity":{"paper_id":631530,"paper_uid":"a27e8af3-cb30-48d7-a49e-1258867acbdb","identity_status":"available","lookup_basis":"semantic_scholar_external_id","compatibility_path":"corpus_id"},"url":"https://sah.borca.ai/papers/205617746"}